Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2022 07:30 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress

Initial data from pivotal FIREFLY-1 study with DAY101 (tovorafenib) expected in June 2022 Targeted enrollment achieved in pivotal FIREFLY-1 study Topline results from pivotal FIREFLY-1 study...
February 28, 2022 16:05 ET | Source: Day One Biopharmaceuticals, Inc.

Day One to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
January 05, 2022 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
November 22, 2021 07:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors

Phase 1b/2 Study Evaluating DAY101 in Combination with Pimasertib, Day One’s MEK Inhibitor, Expected to Begin in First Quarter of 2022 SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) --...
November 18, 2021 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
November 08, 2021 16:50 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports Third Quarter 2021 Financial Results and Corporate Progress

Enrollment Progresses in the Pivotal Phase 2 FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG; Initial Data Expected in 1H 2022 Upcoming CTOS Meeting to Highlight Single Agent Activity of...
November 03, 2021 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
September 13, 2021 07:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Appoints Jaa Roberson as Chief People Officer

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
August 17, 2021 07:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Appoints Scott Garland to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
August 10, 2021 16:05 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports Second Quarter 2021 Financial Results and Corporate Progress

DAY101 Granted Rare Pediatric Disease Designation from FDA DAY101 Granted Orphan Designation from European Commission Dosed the First Patients in Pivotal FIREFLY-1 Clinical Trial of DAY101 in...